48 citations
,
May 2008 in “Drug Discovery Today: Disease Mechanisms”
This review discusses recent advancements in understanding hair follicles, their disorders, and potential therapeutic opportunities, but it reports no new clinical findings.
34 citations
,
July 2010 in “Expert Opinion on Drug Delivery”
This review highlights the need for methodologies to understand and quantify drug penetration into hair follicles as significant drug pathways, noting this area lacks comprehensive articles and reports no new results.
October 2021 in “Journal of Investigative Dermatology”
This study found that interleukin-12 signals play a role in hair follicle immune privilege collapse in ex vivo alopecia areata models, and a TYK2 inhibitor may help prevent or reverse this process.
5 citations
,
June 2022 in “Frontiers in immunology”
This study observed that expanding regulatory T cells in the skin of mice with alopecia areata did not reverse the condition, indicating that additional immunotherapy may be necessary.
263 citations
,
February 2011 in “Journal of Controlled Release”
This study found that medium-sized particles (643 and 646 nm) penetrated deeper into porcine hair follicles in vitro than smaller or larger particles, suggesting size-selective targeting within follicular sites.
Finasteride users have mixed experiences with creatine; some experience increased hair loss, while others do not. Finasteride's DHT-blocking effects might counteract any DHT increase from creatine, but individual responses vary.
GT20029 is an experimental topical treatment for male-pattern hair loss, showing promising results in Phase 2 trials and moving towards Phase 3. It aims to degrade androgen receptors in hair follicles, differing from treatments like finasteride and minoxidil.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.
glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin
What is follistatin, and how does it influence hair follicle growth and regeneration?Follistatin blocks activin and related growth-inhibiting proteins, which in laboratory and animal work is described as keeping hair follicles in their growth phase; the only verifiable human evidence is a single small 2011 phase 1 injection trial, so follistatin remains experimental and is not an approved hair-loss treatment.
Is follistatin safe for use in women or transgender individuals undergoing hormone therapy?No study has tested follistatin in women or transgender people on hormone therapy, and it has no approved human use or established dose; the one relevant signal, from a 2023 randomized study in adolescents with PCOS, links higher follistatin to less favourable metabolic markers, so the published evidence does not support using it in this group.